Shows
COR2ED - Oncology Medical Conversation VideoMetastatic breast cancer: Understanding HER2-low and HER2-ultralow classificationUnderstanding HER2-low and HER2-ultralow classification in mBC
In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binary HER2 model translates into everyday clinical practice.
The experts explore:
Key efficacy data from DESTINY-Breast04 and DESTINY-Breast06, and their impact on the HER2 treatment framework
The clinical relevance of HER2-low and HER2-ultralow categories, and review the CAP reporting template
When and why to perform re-biopsy to detect changes in HER2 expression over time
Best practices for monitoring...
2025-12-1725 minCOR2ED - Oncology Medical ConversationMetastatic breast cancer: Understanding HER2-low and HER2-ultralow classificationUnderstanding HER2-low and HER2-ultralow classification in mBC
In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binary HER2 model translates into everyday clinical practice.
The experts explore:
Key efficacy data from DESTINY-Breast04 and DESTINY-Breast06, and their impact on the HER2 treatment framework
The clinical relevance of HER2-low and HER2-ultralow categories, and review the CAP reporting template
When and why to perform re-biopsy to detect changes in HER2 expression over time
Best practices for monitoring...
2025-12-1725 minCOR2ED - Oncology Medical Conversation VideoUnderstanding EP-NEC: Through Diagnosis, Treatment, and SupportIn this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers.
They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.
Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease.
Key clinical takeaways:
Unlike NETs, E...
2025-11-0727 minCOR2ED - Oncology Medical ConversationUnderstanding EP-NEC: Through Diagnosis, Treatment, and SupportIn this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers.
They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.
Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease.
Key clinical takeaways:
Unlike NETs, E...
2025-11-0727 minCOR2ED - Oncology Medical Conversation VideoExploring the role of targeted radiopharmaceutical treatment in NETsHow are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?
In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.
As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions su...
2025-09-3021 minCOR2ED - Oncology Medical ConversationExploring the role of targeted radiopharmaceutical treatment in NETsHow are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?
In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.
As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions su...
2025-09-3021 minCOR2ED - Oncology Medical Conversation VideoExploring the role of targeted radiopharmaceutical treatment in NETs How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?
In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.
As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions su...
2025-09-1721 minCOR2ED - Oncology Medical ConversationExploring the role of targeted radiopharmaceutical treatment in NETs How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?
In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.
As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions su...
2025-09-1721 minCOR2ED - Oncology Medical Conversation VideoTackling mPDAC: chemotherapy strategies that matterMetastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved.
This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line.
Key clinical takeaways:
mPDAC is notoriously aggressive with a poor prognosis. Patients are generally diagnosed with...
2025-05-1921 minCOR2ED - Oncology Medical ConversationTackling mPDAC: chemotherapy strategies that matterMetastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved.
This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line.
Key clinical takeaways:
mPDAC is notoriously aggressive with a poor prognosis. Patients are generally diagnosed with...
2025-05-1921 minCOR2ED - Oncology Medical Conversation VideoUnderstanding Rare NSCLC Mutations: Insights, access and supportListen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK.
As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari.
Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker testing and treatment of such alterations, together with his own first-hand experience of treating and empowerig patients like Debra in their own treatment journey.
W...
2025-05-1420 minCOR2ED - Oncology Medical ConversationUnderstanding Rare NSCLC Mutations: Insights, access and supportListen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK.
As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari.
Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker testing and treatment of such alterations, together with his own first-hand experience of treating and empowerig patients like Debra in their own treatment journey.
W...
2025-05-1420 minCOR2ED - Oncology Medical Conversation VideoThe HER2 diagnostic and treatment landscape in NSCLCEpisode 2: Navigating common treatment scenarios in HER2-mutant NSCLC
This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.
In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC.
The conversation unfolds to cover;
How to distinguish HER2 alterations from other alterations on biomarker reports
The latest efficacy and safety data of currently approved and emerging treatments for HER...
2025-04-2818 minCOR2ED - Oncology Medical ConversationThe HER2 diagnostic and treatment landscape in NSCLCEpisode 2: Navigating common treatment scenarios in HER2-mutant NSCLC
This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.
In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC.
The conversation unfolds to cover;
How to distinguish HER2 alterations from other alterations on biomarker reports
The latest efficacy and safety data of currently approved and emerging treatments for HER...
2025-04-2818 minCOR2ED - Oncology Medical Conversation VideoThe HER2 Diagnostic and Treatment Landscape in NSCLCEpisode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives
This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.
What makes this conversation so interesting, is that you can gather insights from both the Medical Oncologist perspective with Dr Devika Das, and pathology perspective from Prof. Lopéz-Ríos.
In this episode the discussion focuses identifying HER2-directed NSLC, considering mutations, overexpression and amplifications, whilst not forgetting how best practice in identification of HER2 al...
2025-04-1521 minCOR2ED - Oncology Medical ConversationThe HER2 Diagnostic and Treatment Landscape in NSCLCEpisode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives
This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.
What makes this conversation so interesting, is that you can gather insights from both the Medical Oncologist perspective with Dr Devika Das, and pathology perspective from Prof. Lopéz-Ríos.
In this episode the discussion focuses identifying HER2-directed NSLC, considering mutations, overexpression and amplifications, whilst not forgetting how best practice in identification of HER2 al...
2025-04-1521 minCOR2ED - Oncology Medical Conversation VideoBest practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancerThis podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer.
Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing methods, and clinical decision-making, offering expert insights on how to optimise precision medicine.
Topics include liquid vs. tumour biopsy, single gene vs. broad panel testing, and regional differences in testing practices.
Tune in for a practical, expert-led discussion on how molecular testing can guide personalised treatment and improve patient outcomes.
Key clinical takeaways:
Molecular testing, especially for biomarkers like ESR1...
2025-03-2126 minCOR2ED - Oncology Medical ConversationBest practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancerThis podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer.
Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing methods, and clinical decision-making, offering expert insights on how to optimise precision medicine.
Topics include liquid vs. tumour biopsy, single gene vs. broad panel testing, and regional differences in testing practices.
Tune in for a practical, expert-led discussion on how molecular testing can guide personalised treatment and improve patient outcomes.
Key clinical takeaways:
Molecular testing, especially for biomarkers like ESR1...
2025-03-2126 minCOR2ED - Oncology Medical Conversation VideoAdvanced or recurrent endometrial cancer: Molecular classification and treatment decisionsAdvanced or recurrent endometrial cancer: Molecular classification and treatment decisions
Key clinical takeaways:
MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions
ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations
Lenvatinib plus pembrolizumab is a viable option not only as 2nd line therapy but also as 1st line treatment for patients with non-dMMR advanced/recurrent endometrial cancer who have progressed after prior systemic therapy in any setting
Shared...
2025-02-1711 minCOR2ED - Oncology Medical ConversationAdvanced or recurrent endometrial cancer: Molecular classification and treatment decisionsAdvanced or recurrent endometrial cancer: Molecular classification and treatment decisions
Key clinical takeaways:
MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions
ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations
Lenvatinib plus pembrolizumab is a viable option not only as 2nd line therapy but also as 1st line treatment for patients with non-dMMR advanced/recurrent endometrial cancer who have progressed after prior systemic therapy in any setting
Shared...
2025-02-1711 min
COR2ED - Obstetrics & Gynecology Medical ConversationAdvanced or recurrent endometrial cancer: Molecular classification and treatment decisionsAdvanced or recurrent endometrial cancer: Molecular classification and treatment decisions
Key clinical takeaways:
MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions
ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations
Lenvatinib plus pembrolizumab is a viable option not only as 2nd line therapy but also as 1st line treatment for patients with non-dMMR advanced/recurrent endometrial cancer who have progressed after prior systemic therapy in any setting
Shared...
2025-02-1711 minCOR2ED - Oncology Medical Conversation VideoIntermediate HCC – The evolving role of IOIntermediate HCC – The evolving role of IO
In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers Drs Rohit and Rahul Gosain, the discussion focuses on the evolving role of immunotherapy (IO) in intermediate HCC. The episode explores multimodal approaches that combine IO and IO-based therapies with loco-regional treatments and highlights the essential role of a multidisciplinary care team.
Joined by Drs Nina Sanford (radiation oncologist), Mark Yarchoan (medical oncologist) and Ed Kim (interventional radiologist), the experts provide a brief overview of current treatment options for intermediate HCC, addre...
2025-01-2027 minCOR2ED - Oncology Medical ConversationIntermediate HCC – The evolving role of IOIntermediate HCC – The evolving role of IO
In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers Drs Rohit and Rahul Gosain, the discussion focuses on the evolving role of immunotherapy (IO) in intermediate HCC. The episode explores multimodal approaches that combine IO and IO-based therapies with loco-regional treatments and highlights the essential role of a multidisciplinary care team.
Joined by Drs Nina Sanford (radiation oncologist), Mark Yarchoan (medical oncologist) and Ed Kim (interventional radiologist), the experts provide a brief overview of current treatment options for intermediate HCC, addre...
2025-01-2027 minCOR2ED - Obstetrics & Gynecology Medical ConversationLatest strategies for prevention and management of PPH (2)Appropriate management of postpartum hemorrhage (PPH) requires prompt diagnosis and treatment. However, there's some debate on various PPH prevention and management strategies and the corresponding scientific evidence. What do you believe is the right strategy to prevent and treat PPH?
In this third episode of a four-part podcast series on severe PPH, Prof. Loïc Sentilhes (Professor of Obstetrics and Gynecology, Chairman of the Gynecology and Obstetric Department at Bordeaux University Hospital, France) and Prof. Christian von Heymann (Chief Physician of the Clinic for Anesthesia, Intensive Care Medicine and Pain Therapy and Medical Director at the Vivantes C...
2025-01-1334 minCOR2ED - Oncology Medical Conversation VideoIntermediate HCC – treatment options and strategiesIn the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr Maria Reig and Interventional Radiologist Dr Emil Cohen to explore the complexities of managing intermediate-stage hepatocellular carcinoma (HCC). Together, they unpack treatment options and strategies through a dynamic and engaging discussion rooted in real-world clinical practice.
Key topics include:
An overview of the available treatment options for this heterogeneous patient population with intermediate HCC
A deep dive into loco-regional therapies, including TACE, TARE (Y-90), and SBRT
Exploring the role of systemic treatments in p...
2025-01-0720 minCOR2ED - Oncology Medical ConversationIntermediate HCC – treatment options and strategiesIn the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr Maria Reig and Interventional Radiologist Dr Emil Cohen to explore the complexities of managing intermediate-stage hepatocellular carcinoma (HCC). Together, they unpack treatment options and strategies through a dynamic and engaging discussion rooted in real-world clinical practice.
Key topics include:
An overview of the available treatment options for this heterogeneous patient population with intermediate HCC
A deep dive into loco-regional therapies, including TACE, TARE (Y-90), and SBRT
Exploring the role of systemic treatments in p...
2025-01-0720 min
COR2ED - Rare Diseases Medical ConversationShort-stature conditions, including SPIGFDHear from Dr Andrew Dauber and Dr Marta Ramón Krauel in this podcast as they explore short stature conditions, including SPIGFD (severe primary IGF-1 deficiency) / growth hormone resistance, through real patient cases and clinical insights. While growth hormone deficiency is a well-known cause of short stature, this discussion covers patient cases where growth hormone levels are normal or even elevated, yet IGF-1 levels remain low—a hallmark of primary IGF-1 deficiency.
Gain valuable knowledge on identifying and managing this rare condition, with practical takeaways for clinical practice.
Key clinical takeaways:
Growth hormone resistance can rang...
2024-12-1024 minCOR2ED - Oncology Medical Conversation VideoHCC podcast series part 2: 2nd line treatment in advanced HCC and when to switchJoin the Oncology Brothers, Drs Rahul and Rohit Gosain, as they host an insightful discussion with Dr Lorenza Rimassa and Prof. Arndt Vogel. In the second of a 4-part podcast series, this episode dives into 2nd line treatment selection in advanced HCC and the key considerations for deciding when to switch therapies.
Topics include:
2nd line options for advanced HCC after 1st line TKIs and IO-based therapies
Sequencing strategies and clinical practice approaches
Key data supporting 2nd line decisions
Factors to consider when transitioning to 2nd line therapy
Key clinical takeaways:
Prospe...
2024-12-0326 minCOR2ED - Oncology Medical ConversationHCC podcast series part 2: 2nd line treatment in advanced HCC and when to switchJoin the Oncology Brothers, Drs Rahul and Rohit Gosain, as they host an insightful discussion with Dr Lorenza Rimassa and Prof. Arndt Vogel. In the second of a 4-part podcast series, this episode dives into 2nd line treatment selection in advanced HCC and the key considerations for deciding when to switch therapies.
Topics include:
2nd line options for advanced HCC after 1st line TKIs and IO-based therapies
Sequencing strategies and clinical practice approaches
Key data supporting 2nd line decisions
Factors to consider when transitioning to 2nd line therapy
Key clinical takeaways:
Prospe...
2024-12-0326 minCOR2ED - Oncology Medical Conversation VideoTesting to treatment of BRAF-mutant metastatic NSCLCTesting to treatment of BRAF-mutant metastatic NSCLC
In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metastatic non-small cell lung cancer (NSCLC), the testing strategies and first- and second-line treatment options for these patients.
The discussion focuses on which BRAF mutations to test for and when in the patient journey to test, before moving on to consider if NGS broad panel testing should be applied routinely for patients. Various treatments are considered, along with which decision criteria come into play when selecting a par...
2024-11-2523 minCOR2ED - Oncology Medical ConversationTesting to treatment of BRAF-mutant metastatic NSCLC Testing to treatment of BRAF-mutant metastatic NSCLC
In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metastatic non-small cell lung cancer (NSCLC), the testing strategies and first- and second-line treatment options for these patients.
The discussion focuses on which BRAF mutations to test for and when in the patient journey to test, before moving on to consider if NGS broad panel testing should be applied routinely for patients. Various treatments are considered, along with which decision criteria come into play when selecting a part...
2024-11-2523 minCOR2ED - Oncology Medical Conversation VideoHCC podcast series part 1: The use of IO in unresectable HCCIn the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC (uHCC) and take a deep dive into the different treatment options first-line focusing on IO and IO based combinations. Topics include:
Current first-line systemic treatment options for uHCC
Efficacy and safety of IO and IO combinations including practical aspects of identifying and managing immune-mediated AEs
How to select between the two first-line IO-based treatment options based on clinical factors and practical considerations
Key clinica...
2024-11-2123 minCOR2ED - Oncology Medical ConversationHCC podcast series part 1: The use of IO in unresectable HCCIn the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC (uHCC) and take a deep dive into the different treatment options first-line focusing on IO and IO based combinations. Topics include:
Current first-line systemic treatment options for uHCC
Efficacy and safety of IO and IO combinations including practical aspects of identifying and managing immune-mediated AEs
How to select between the two first-line IO-based treatment options based on clinical factors and practical considerations
Key clinica...
2024-11-2123 minCOR2ED - Oncology Medical Conversation VideoBRAF-mutated CRC: testing to treatmentExperts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available treatments for these patients.
They consider the prevalence and types of BRAF mutations in CRC patients and highlight the poor prognosis for these patients. The experts also cover the optimal time and methods for testing for BRAF mutations, as well as the targeted therapies currently available for BRAF-mutated CRC.
Several key trials are discussed, including the BEACON trial which resulted in encorafenib plus cetuximab being the standard of car...
2024-11-0825 minCOR2ED - Oncology Medical ConversationBRAF-mutated CRC: testing to treatmentExperts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available treatments for these patients.
They consider the prevalence and types of BRAF mutations in CRC patients and highlight the poor prognosis for these patients. The experts also cover the optimal time and methods for testing for BRAF mutations, as well as the targeted therapies currently available for BRAF-mutated CRC.
Several key trials are discussed, including the BEACON trial which resulted in encorafenib plus cetuximab being the standard of car...
2024-11-0825 minCOR2ED - Oncology Medical Conversation VideoNeuroendocrine tumours (NETs) – Shared decision-making. Part 2: Individualising treatment decisionsIn this second episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins explore shared decision-making, between patient and physician.
The speakers discuss different treatment settings, including home vs hospital-based injections, as well as the importance of individualising treatment decisions, as there is often no standard therapy for patients with NETs. Finally, they look at some of the studies reporting patient preferences, and how the data can be used to inform patient decisions.
Prefer to watch and listen? Watch the vi...
2024-09-1122 minCOR2ED - Rare Diseases Medical ConversationNeuroendocrine tumours (NETs) – Shared decision-making. Part 2: Individualising treatment decisionsIn this second episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins explore shared decision-making, between patient and physician.
The speakers discuss different treatment settings, including home vs hospital-based injections, as well as the importance of individualising treatment decisions, as there is often no standard therapy for patients with NETs. Finally, they look at some of the studies reporting patient preferences, and how the data can be used to inform patient decisions.
Prefer to watch and listen? Watch the vi...
2024-09-1122 minCOR2ED - Oncology Medical ConversationNeuroendocrine tumours (NETs) – Shared decision-making. Part 2: Individualising treatment decisionsIn this second episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins explore shared decision-making, between patient and physician.
The speakers discuss different treatment settings, including home vs hospital-based injections, as well as the importance of individualising treatment decisions, as there is often no standard therapy for patients with NETs. Finally, they look at some of the studies reporting patient preferences, and how the data can be used to inform patient decisions.
Prefer to watch and listen? Watch the vi...
2024-09-1122 minCOR2ED - Oncology Medical Conversation VideoNeuroendocrine tumours (NETs) – Shared decision-making. Part 1: Patient journeyIn this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins discuss the importance of communication and collaboration during consultations. This can include how to make a patient feel as comfortable and in control as possible, as well as recognising their goals and concerns.
The speakers share their real-life experiences of what makes a good consultation, from the perspectives of both a patient and a physician. They also explore the importance of support networks, individualising treatment, and the impact of NET and NET...
2024-09-1129 minCOR2ED - Rare Diseases Medical ConversationNeuroendocrine tumours (NETs) – Shared decision-making. Part 1: Patient journeyIn this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins discuss the importance of communication and collaboration during consultations. This can include how to make a patient feel as comfortable and in control as possible, as well as recognising their goals and concerns.
The speakers share their real-life experiences of what makes a good consultation, from the perspectives of both a patient and a physician. They also explore the importance of support networks, individualising treatment, and the impact of NET and NET...
2024-09-1129 minCOR2ED - Oncology Medical ConversationNeuroendocrine tumours (NETs) – Shared decision-making. Part 1: Patient journeyIn this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins discuss the importance of communication and collaboration during consultations. This can include how to make a patient feel as comfortable and in control as possible, as well as recognising their goals and concerns.
The speakers share their real-life experiences of what makes a good consultation, from the perspectives of both a patient and a physician. They also explore the importance of support networks, individualising treatment, and the impact of NET and NET...
2024-09-1129 minCOR2ED - Rare Diseases Medical ConversationRegional differences in NET: Treatment and future developmentsIn the second episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss how to optimize treatment for people living with NETs and future developments in the field which may help to improve patient outcomes. The episode includes information on different treatment options and modalities, and well as best practice on identifying which patients may benefit most from particular treatments using available biomarkers.
Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neur...
2024-05-2821 minCOR2ED - Rare Diseases Medical ConversationRegional differences in NET: Epidemiology, diagnosis, and referral strategiesIn this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, and patient pathways, as well as look to future developments.
NETs are complex, rare diseases. Their optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. The best possible patient journey is impacted by regional differences in management strategies, referral pathways, and availability of diagnostic modalities and treatments.. Are you aware of the epidemiology of NETs and current best practices for diagnosis, referral strategies, and treatment for NETs? Or how regional d...
2024-05-2821 minCOR2ED - Oncology Medical ConversationRegional differences in NET: Treatment and future developmentsIn the second episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss how to optimize treatment for people living with NETs and future developments in the field which may help to improve patient outcomes. The episode includes information on different treatment options and modalities, and well as best practice on identifying which patients may benefit most from particular treatments using available biomarkers.
Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neur...
2024-05-2821 minCOR2ED - Oncology Medical ConversationRegional differences in NET: Epidemiology, diagnosis, and referral strategiesIn this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, and patient pathways, as well as look to future developments.
NETs are complex, rare diseases. Their optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. The best possible patient journey is impacted by regional differences in management strategies, referral pathways, and availability of diagnostic modalities and treatments.. Are you aware of the epidemiology of NETs and current best practices for diagnosis, referral strategies, and treatment for NETs? Or how regional d...
2024-05-2821 minCOR2ED - Oncology Medical Conversation VideoRegional differences in NET: Treatment and future developmentsIn the second episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss how to optimize treatment for people living with NETs and future developments in the field which may help to improve patient outcomes. The episode includes information on different treatment options and modalities, and well as best practice on identifying which patients may benefit most from particular treatments using available biomarkers.
Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neur...
2024-05-2821 minCOR2ED - Oncology Medical Conversation VideoRegional differences in NET: Epidemiology, diagnosis, and referral strategiesIn this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, and patient pathways, as well as look to future developments.
NETs are complex, rare diseases. Their optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. The best possible patient journey is impacted by regional differences in management strategies, referral pathways, and availability of diagnostic modalities and treatments.. Are you aware of the epidemiology of NETs and current best practices for diagnosis, referral strategies, and treatment for NETs? Or how regional d...
2024-05-2821 minCOR2ED - Oncology Medical Conversation VideoUnderstanding the needs of different patient populations in colorectal cancerDo you understand the needs of different patient groups with colorectal cancer? Do you know about the barriers to treatment experienced by different ethnicities, socioeconomic groups and younger patients? In this insightful podcast facilitated by Oncology Brothers Drs Rahul and Rohit Gosain, Prof Tanios Bekaii-Saab and Ms Deneen Richmond provide their perspectives as a practising oncologist and a cancer survivor.
They discuss the different methods of communication required to build trust in patients from specific ethnic groups (African American, Hispanic and Asian American). They also talk about the unique challenges experienced by younger patients with colorectal cancer. Thro...
2024-05-1525 minCOR2ED - Oncology Medical ConversationUnderstanding the needs of different patient populations in colorectal cancerDo you understand the needs of different patient groups with colorectal cancer? Do you know about the barriers to treatment experienced by different ethnicities, socioeconomic groups and younger patients? In this insightful podcast facilitated by Oncology Brothers Drs Rahul and Rohit Gosain, Prof Tanios Bekaii-Saab and Ms Deneen Richmond provide their perspectives as a practising oncologist and a cancer survivor.
They discuss the different methods of communication required to build trust in patients from specific ethnic groups (African American, Hispanic and Asian American). They also talk about the unique challenges experienced by younger patients with colorectal cancer. Thro...
2024-05-1525 minCOR2ED - Oncology Medical Conversation VideoInterpreting real-world evidence in later-line mCRCWhat are the challenges and considerations when using real-world evidence to inform your clinical practice? How can data from real-world studies be used to complement data from clinical trials?
In this podcast, GI oncologists Prof. Tanios Bekaii-Saab and Prof. Shubham Pant discuss how to interpret real-world evidence in later line metastatic colorectal cancer. They also discuss data from ASCO GI 2024 and how these results can be used to inform treatment decisions.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full tra...
2024-05-0727 minCOR2ED - Oncology Medical ConversationInterpreting real-world evidence in later-line mCRCWhat are the challenges and considerations when using real-world evidence to inform your clinical practice? How can data from real-world studies be used to complement data from clinical trials?
In this podcast, GI oncologists Prof. Tanios Bekaii-Saab and Prof. Shubham Pant discuss how to interpret real-world evidence in later line metastatic colorectal cancer. They also discuss data from ASCO GI 2024 and how these results can be used to inform treatment decisions.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full tra...
2024-05-0727 min
Hematology Medical ConversationThrombophilia Screening: Best Practices and Who Should be Tested?What does thrombophilia testing mean for patients or their families? Do you know when and who to test for thrombophilia? In this podcast, experts Prof. Saskia Middeldorp and Prof. Jean Connors explore the diagnostic challenges for thrombophilia and which patients can benefit most from screening. In specific situations, testing can be crucial, but not always. Before testing, it is important to understand whether testing is needed and consider how it will provide support for decision making. ASH guidelines may be helpful. The experts discuss how these recommendations should be applied in general practice, as some caution is recommended.
2024-05-0127 minCOR2ED - Oncology Medical ConversationCáncer de ovario: dificultades en la fase preanalítica y pruebas de biomarcadores¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de ovario, y cómo podemos solucionarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Usted está viendo el tercer episodio de una serie de podcast de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.
En este episodio, escuchará a la profesora adjunta Martina Murphy (médica oncóloga) y a la profesora adjunta Caterina Marchiò (anatomopatóloga) hablar sobre las dificultades en la fase preanalítica y las pru...
2024-04-2532 minCOR2ED - Oncology Medical ConversationCâncer de ovário: Desafios da fase pré-analítica e teste de biomarcadoresQuais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de ovário e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está assistindo à parte 3 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.
Neste episódio, você ouvirá a Professora Adjunta Martina Murphy (oncologista) e a Professora Adjunta Caterina Marchiò (patologista) esclarecerem quais são os desafios da fase pré-analítica e do...
2024-04-2532 minCOR2ED - Oncology Medical ConversationCáncer de próstata: dificultades en la fase preanalítica y pruebas de biomarcadores¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de próstata, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Está escuchando la parte 1 de una serie de podcast en video de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.
En este episodio, escuchará al especialista en genómica del cáncer genitourinario, el Dr. Alexander Wyatt, y al oncólogo médico, el Dr. Petros Grivas, profundizar sobre las dificultades en la...
2024-04-2529 minCOR2ED - Oncology Medical ConversationCâncer de Próstata: Desafios da Fase Pré-Analítica e Teste de BiomarcadoresQuais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de próstata e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está ouvindo a parte 1 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.
Neste episódio, você ouvirá o especialista em genoma do câncer geniturinário, Dr. Alexander Wyatt, e o oncologista, Dr. Petros Grivas, esclarecerem quais são os desafios d...
2024-04-2529 minCOR2ED - Oncology Medical ConversationCáncer de pulmón: dificultades en la fase preanalítica y pruebas de biomarcadores¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de pulmón, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Está viendo la parte 2 de una serie de podcast en video de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.
En este episodio, escuchará a la Dra. Bruna Pellini (médica oncóloga) y al Dr. Semir Vranić (anatomopatólogo) profundizar sobre las dificultades en la fase preanalítica y las pruebas de biomarcad...
2024-04-2527 minCOR2ED - Oncology Medical ConversationCâncer de pulmão: Desafios da fase pré-analítica e teste de biomarcadoresQuais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de pulmão e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está assistindo à parte 2 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.
Neste episódio, você ouvirá a Dra. Bruna Pellini (oncologista) e Semir Vranić (patologista) esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadore...
2024-04-2527 minCOR2ED - Oncology Medical Conversation VideoCáncer de ovario: dificultades en la fase preanalítica y pruebas de biomarcadores¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de ovario, y cómo podemos solucionarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Usted está viendo el tercer episodio de una serie de podcast de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.
En este episodio, escuchará a la profesora adjunta Martina Murphy (médica oncóloga) y a la profesora adjunta Caterina Marchiò (anatomopatóloga) hablar sobre las dificultades en la fase preanalítica y las pru...
2024-04-2532 minCOR2ED - Oncology Medical Conversation VideoCâncer de ovário: Desafios da fase pré-analítica e teste de biomarcadoresQuais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de ovário e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está assistindo à parte 3 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.
Neste episódio, você ouvirá a Professora Adjunta Martina Murphy (oncologista) e a Professora Adjunta Caterina Marchiò (patologista) esclarecerem quais são os desafios da fase pré-analítica e do...
2024-04-2532 minCOR2ED - Oncology Medical Conversation VideoCâncer de pulmão: Desafios da fase pré-analítica e teste de biomarcadoresQuais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de pulmão e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está assistindo à parte 2 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.
Neste episódio, você ouvirá a Dra. Bruna Pellini (oncologista) e Semir Vranić (patologista) esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadore...
2024-04-2527 minCOR2ED - Oncology Medical Conversation VideoCáncer de pulmón: dificultades en la fase preanalítica y pruebas de biomarcadores¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de pulmón, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Está viendo la parte 2 de una serie de podcast en video de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.
En este episodio, escuchará a la Dra. Bruna Pellini (médica oncóloga) y al Dr. Semir Vranić (anatomopatólogo) profundizar sobre las dificultades en la fase preanalítica y las pruebas de biomarcad...
2024-04-2527 minCOR2ED - Oncology Medical Conversation VideoCâncer de Próstata: Desafios da Fase Pré-Analítica e Teste de BiomarcadoresQuais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de próstata e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está ouvindo a parte 1 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.
Neste episódio, você ouvirá o especialista em genoma do câncer geniturinário, Dr. Alexander Wyatt, e o oncologista, Dr. Petros Grivas, esclarecerem quais são os desafios d...
2024-04-2529 minCOR2ED - Oncology Medical Conversation VideoCáncer de próstata: dificultades en la fase preanalítica y pruebas de biomarcadores¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de próstata, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Está escuchando la parte 1 de una serie de podcast en video de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.
En este episodio, escuchará al especialista en genómica del cáncer genitourinario, el Dr. Alexander Wyatt, y al oncólogo médico, el Dr. Petros Grivas, profundizar sobre las dificultades en la...
2024-04-2529 minCOR2ED - Oncology Medical ConversationmCRC: Optimising patient outcomes with late-line treatmentWhat treatment options are available for patients with metastatic colorectal cancer who have already progressed through multiple lines of therapy? How can we select the right treatment for the right patient?
Medical oncologists Assoc. Prof. Gerald Prager (Austria) and Dr Victor Hugo Fonseca de Jesus draw from their own clinical expertise and data from clinical trials to provide their perspectives on these questions. They discuss how to manage side effects from available treatments to maximise survival benefit whilst maintaining quality of life and consider what the future holds for later-line treatment in metastatic colorectal cancer.
Pre...
2024-03-2823 minCOR2ED - Oncology Medical Conversation VideomCRC: Optimising patient outcomes with late-line treatmentWhat treatment options are available for patients with metastatic colorectal cancer who have already progressed through multiple lines of therapy? How can we select the right treatment for the right patient?
Medical oncologists Assoc. Prof. Gerald Prager (Austria) and Dr Victor Hugo Fonseca de Jesus draw from their own clinical expertise and data from clinical trials to provide their perspectives on these questions. They discuss how to manage side effects from available treatments to maximise survival benefit whilst maintaining quality of life and consider what the future holds for later-line treatment in metastatic colorectal cancer.
Pre...
2024-03-2823 minCOR2ED - Oncology Medical Conversation VideoPerseverance pays off – Looking beyond the obvious mutations in NSCLCWhy is it important to perform comprehensive molecular testing in non-small cell lung cancer to look beyond the obvious mutations? Which biomarker tests are best andwhen should testing be performed?
In this podcast episode, you’ll hear Prof. Mark Socinski (medical oncologist) and Prof. Frédérique Penault-Llorca (pathologist) discuss why perseverance with molecular testing pays off in non-small cell lung cancer (NSCLC).
As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in NSCLC, which biomarker testing approaches should be considered standard of care, and the importance of close...
2024-03-2826 minCOR2ED - Oncology Medical ConversationPerseverance pays off – Looking beyond the obvious mutations in NSCLCWhy is it important to perform comprehensive molecular testing in non-small cell lung cancer to look beyond the obvious mutations? Which biomarker tests are best andwhen should testing be performed?
In this podcast episode, you’ll hear Prof. Mark Socinski (medical oncologist) and Prof. Frédérique Penault-Llorca (pathologist) discuss why perseverance with molecular testing pays off in non-small cell lung cancer (NSCLC).
As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in NSCLC, which biomarker testing approaches should be considered standard of care, and the importance of close...
2024-03-2826 minHematology Medical ConversationSevere postpartum hemorrhage (PPH) series: Part 4Innovation is the key to achieving success in the future, including recent scientific research to explore novel therapeutic options to improve the treatment of severe postpartum hemorrhage (PPH). If you're curious about the latest advancements in this field and how they can impact future treatment strategies for women who suffer from severe PPH, then listen to the fourth and final part of a podcast series on severe PPH.
Experts will discuss the latest treatment advances and their perception of how the management of PPH will evolve in the future.
Don't miss out on this opportunity...
2024-02-2724 minCOR2ED - Obstetrics & Gynecology Medical ConversationSevere postpartum hemorrhage (PPH) series: Part 4Innovation is the key to achieving success in the future, including recent scientific research to explore novel therapeutic options to improve the treatment of severe postpartum hemorrhage (PPH). If you're curious about the latest advancements in this field and how they can impact future treatment strategies for women who suffer from severe PPH, then listen to the fourth and final part of a podcast series on severe PPH.
Experts will discuss the latest treatment advances and their perception of how the management of PPH will evolve in the future.
Don't miss out on this opportunity...
2024-02-2724 minCOR2ED - Oncology Medical Conversation VideoOvarian cancer: Pre-analytical phase challenges and biomarker testingWhat are the common pre-analytical phase challenges in ovarian cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are watching part 3 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs Rohit and Rahul Gosain.
In this episode, you’ll hear Assoc. Prof. Martina Murphy (medical oncologist) and Assoc. Prof. Caterina Marchiò (pathologist) shine a spotlight on the pre-analytical phase challenges and biomarker testing in ovarian cancer.
As the conversation unfolds, the experts explain why it’s...
2024-02-2332 minCOR2ED - Oncology Medical ConversationOvarian cancer: Pre-analytical phase challenges and biomarker testingWhat are the common pre-analytical phase challenges in ovarian cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are watching part 3 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs Rohit and Rahul Gosain.
In this episode, you’ll hear Assoc. Prof. Martina Murphy (medical oncologist) and Assoc. Prof. Caterina Marchiò (pathologist) shine a spotlight on the pre-analytical phase challenges and biomarker testing in ovarian cancer.
As the conversation unfolds, the experts explain why it’s...
2024-02-2332 minHematology Medical ConversationThrombophilia: Clinical overview and impact on patientsThrombophilia: Clinical overview and impact on patients
What do you know about thrombophilia? Is it acquired or inherited, and what is the impact on patients? This is the first in a 2-part podcast series focusing on Thrombophilia.
In this episode, you will hear from Prof. Cedric Hermans, who is the Head of the division of Hematology, the Hemostasis and Thrombosis Unit and Hemophilia center of the Saint-Luc University hospital in Brussels, Belgium, and Prof. Sabine Eichinger, who is the Head of the Coagulation Clinic at the Medical University of Vienna, Austria. The experts discuss the...
2024-02-0127 minCOR2ED - Oncology Medical Conversation VideoLung cancer: Pre-analytical phase challenges and biomarker testingWhat are the common pre-analytical phase challenges in lung cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are watching part 2 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs Rohit and Rahul Gosain.
In this episode, you’ll hear Dr Bruna Pellini (medical oncologist) and Semir Vranić (pathologist) shine a spotlight on the pre-analytical phase challenges and biomarker testing in lung cancer.
As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in lung...
2024-01-2527 minCOR2ED - Oncology Medical ConversationLung cancer: Pre-analytical phase challenges and biomarker testingWhat are the common pre-analytical phase challenges in lung cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are watching part 2 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs Rohit and Rahul Gosain.
In this episode, you’ll hear Dr Bruna Pellini (medical oncologist) and Semir Vranić (pathologist) shine a spotlight on the pre-analytical phase challenges and biomarker testing in lung cancer.
As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in lung...
2024-01-2527 minCOR2ED - Obstetrics & Gynecology Medical ConversationLatest strategies for prevention and management of PPHAppropriate management of postpartum hemorrhage (PPH) requires prompt diagnosis and treatment. However, there's some debate on various PPH prevention and management strategies and the corresponding scientific evidence. What do you believe is the right strategy to prevent and treat PPH?
In this third episode of a four-part podcast series on severe PPH, Prof. Loïc Sentilhes (Professor of Obstetrics and Gynecology, Chairman of the Gynecology and Obstetric Department at Bordeaux University Hospital, France) and Prof. Christian von Heymann (Chief Physician of the Clinic for Anesthesia, Intensive Care Medicine and Pain Therapy and Medical Director at the Vivantes C...
2024-01-1734 minCOR2ED - Rare Diseases Medical ConversationShort stature: Severe primary IGF-I deficiency (SPIGFD). Part 2Comprehensive biochemical and genetic testing allows for the identification of classical and non-classical forms of primary IGF-I deficiency and can identify overlapping syndromes. Are you updated on the treatment for patients with severe primary IGF-I deficiency? Listen as expert pediatric endocrinologists delve into this rare growth disorder.
Join Prof. Helen Storr (Professor and Honorary Consultant in Paediatric Endocrinology at Queen Mary University, London and Barts Health Trust, London, UK) and Prof. Andrew Dauber (Chief of Endocrinology, Children's National Hospital. Washington, DC, USA) as they engage in a conversation about the diagnosis and management of patients with severe pr...
2023-12-1225 minCOR2ED - Oncology Medical Conversation VideoPrecision oncology: An overview of tumour agnostic therapiesWhat are tumour agnostic cancer treatments and which biomarkers do they target?
Join Prof. David Hong (Medical Oncologist at MD Anderson Cancer Center, Houston, Texas, United States) and Dr Tracy L Stockley (Pathologist and Geneticist at University Health Network, Toronto, Canada) as they deep dive into the topic of tumour agnostic therapies in this video podcast.
As the conversation unfolds, the precision oncology experts explore the issues and challenges associated with developing tumour agnostic therapies and discuss how these treatments differ from others.
Listen to deepen your understanding of:
Biomarker targets associated...
2023-12-0722 minCOR2ED - Oncology Medical ConversationPrecision oncology: An overview of tumour agnostic therapiesWhat are tumour agnostic cancer treatments and which biomarkers do they target?
Join Prof. David Hong (Medical Oncologist at MD Anderson Cancer Center, Houston, Texas, United States) and Dr Tracy L Stockley (Pathologist and Geneticist at University Health Network, Toronto, Canada) as they deep dive into the topic of tumour agnostic therapies in this video podcast.
As the conversation unfolds, the precision oncology experts explore the issues and challenges associated with developing tumour agnostic therapies and discuss how these treatments differ from others.
Listen to deepen your understanding of:
Biomarker targets associated...
2023-12-0722 minHematology Medical ConversationGene therapy and gene-modified cell therapy in rare diseasesGene therapy and gene-modified cell therapies have a great potential for rare diseases to either help patients to cure their disease or improve their lives. Did you know that gene therapy will probably become a major treatment option for many rare diseases in the near future? Listen as expert hematologists delve into this topic and take hemophilia as a practical example.
Join Prof. Cédric Hermans (Head of the Division of Haematology, the Hemostasis and Thrombosis Unit and the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium) and Prof. Miguel Escobar (Professor of Medicine and P...
2023-12-0727 minCOR2ED - Rare Diseases Medical ConversationShort stature: Key challenges in diagnosis and management. Part 1Do you know how to differentiate between growth hormone deficiency (or GHD) and primary IGF-I deficiency (or growth hormone resistance) and the key challenges in the diagnosis and management of patients with short stature conditions?
For children presenting with short stature, an early and correct diagnosis is essential to allow children to achieve their full growth potential with appropriate treatment. Listen as expert pediatric endocrinologists delve into these rare growth disorders.
Join Prof. Philippe Backeljauw (Professor at Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, USA) and Prof. Dr. Joachim Woelfle (Chairman...
2023-12-0633 minCOR2ED - Rare Diseases Medical ConversationGene therapy and gene-modified cell therapy in rare diseasesGene therapy and gene-modified cell therapies have a great potential for rare diseases to either help patients to cure their disease or improve their lives. Did you know that gene therapy will probably become a major treatment option for many rare diseases in the near future? Listen as expert hematologists delve into this topic and take hemophilia as a practical example.
Join Prof. Cédric Hermans (Head of the Division of Haematology, the Hemostasis and Thrombosis Unit and the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium) and Prof. Miguel Escobar (Professor of Medicine and P...
2023-12-0627 minCOR2ED - Oncology Medical Conversation VideoProstate Cancer: Pre-Analytical Phase Challenges and Biomarker TestingWhat are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain.
In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer.
As the conversation unfolds, the experts explain why it’s so import...
2023-12-0629 minCOR2ED - Oncology Medical ConversationProstate Cancer: Pre-Analytical Phase Challenges and Biomarker TestingWhat are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain.
In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer.
As the conversation unfolds, the experts explain why it’s so import...
2023-12-0629 min
COR2ED Medical EducationDiagnosis and management of short stature patientsDo you know how to differentiate between growth hormone deficiency (or GHD) and primary IGF-I deficiency (or growth hormone resistance) and the key challenges in the diagnosis and management of patients with short stature conditions?
For children presenting with short stature, an early and correct diagnosis is essential to allow children to achieve their full growth potential with appropriate treatment. Listen as expert pediatric endocrinologists delve into these rare growth disorders.
Join Prof. Philippe Backeljauw (Professor at Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, USA) and Prof. Dr. Joachim Woelfle (Chairman...
2023-12-0433 minCOR2ED Medical EducationDiagnosis and management of short stature patientsDo you know how to differentiate between growth hormone deficiency (or GHD) and primary IGF-I deficiency (or growth hormone resistance) and the key challenges in the diagnosis and management of patients with short stature conditions?
For children presenting with short stature, an early and correct diagnosis is essential to allow children to achieve their full growth potential with appropriate treatment. Listen as expert pediatric endocrinologists delve into these rare growth disorders.
Join Prof. Philippe Backeljauw (Professor at Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, USA) and Prof. Dr. Joachim Woelfle (Chairman...
2023-12-0433 minCOR2ED Medical EducationGene therapy and gene-modified cell therapy in rare diseasesGene therapy and gene-modified cell therapies have a great potential for rare diseases to either help patients to cure their disease or improve their lives. Did you know that gene therapy will probably become a major treatment option for many rare diseases in the near future? Listen as expert hematologists delve into this topic and take hemophilia as a practical example.
Join Prof. Cédric Hermans (Head of the Division of Haematology, the Hemostasis and Thrombosis Unit and the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium) and Prof. Miguel Escobar (Professor of Medicine and P...
2023-11-2927 min
COR2ED Medical EducationProstate Cancer: Pre-Analytical Phase Challenges and Biomarker TestingWhat are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain.
In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer.
As the conversation unfolds, the experts explain why it’s so import...
2023-11-2129 minCOR2ED Medical EducationProstate Cancer: Pre-Analytical Phase Challenges and Biomarker TestingWhat are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain.
In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer.
As the conversation unfolds, the experts explain why it’s so import...
2023-11-2029 min
COR2ED Medical EducationManagement of Skin Toxicity with Multikinase InhibitorsCOR2ED Medical Education: In this podcast, Beth Wittmer RN, Director of Care Management at Florida Cancer Specialists, USA and Prof. Hans Prenen, GI Medical Oncologist from Antwerp University Hospital, Belgium, discuss the management of dermatological side effects that patients may experience when receiving treatment with multikinase inhibitors, such as regorafenib, sunitinib, cabozantinib amongst others. They discuss the different skin related side effects that a patient may experience such as hand foot skin reactions, rash, hair and nail changes as well as mucosal changes. The experts note that these side effects can affect a patient emotionally and impair their q...
2022-06-0822 min
COR2ED Medical EducationImmune tolerance induction in the era of emicizumabCOR2ED Medical Education: In this podcast, two haematology experts discuss their views on the use of immune tolerance induction (ITI) in haemophilia. Prof. Jan Astermark, professor of Clinical Coagulation Medicine from Sweden, and Dr. Katharina Holstein, Haematologist from Germany, talk about whether ITI is still the first choice in patients with haemophilia A with inhibitors. A recent survey on the use of ITI in Europe, conducted by the speakers and other members of the European Collaborative Haemophilia Network, forms the basis of the discussion. In March 2022 the results of the survey were published in the journal Haemophilia.
2022-05-0322 min
COR2ED Medical EducationHigh-Risk Cytogenetics in MM: Choosing the Best Treatment Regimen Ep 3COR2ED Medical Education: In this podcast episode, myeloma experts Dr. María Victoria Mateos (Haematologist at the University Hospital Salamanca, Spain) and Dr. Alexander Lesokhin (Associate Attending on the Myeloma Service at the Memorial Sloan Kettering Cancer Center, New York, NY, USA) discuss how they choose the best treatment regimen for patients with multiple myeloma and a high-risk cytogenetic profile.
Firstly, they discuss the treatment options available for patients with high-risk cytogenetics in the US and in Europe. However, the key question is how to decide, for each individual, which treatment option is the best one. Dr...
2022-03-1619 min
COR2ED Medical EducationProstate Cancer highlights from ASCO GU 2022COR2ED Medical Education: Dr Alicia Morgans, Genitourinary Medical Oncologist at the Dana-Farber Cancer Institute in the United States and Dr. Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States discuss ‘Prostate Cancer Highlights from ASCO GU 2022’ in this GU CONNECT podcast.
In this podcast, the experts review data from a number of key plenary sessions from ASCO GU 2022 and discuss potential implications for clinical practice. The ARASENS trial is covered first which looked at triplet therapy in the form of ADT plus docetaxel and darolutamide in pati...
2022-03-0838 min
COR2ED Medical EducationProphylaxis in children with haemophiliaCOR2ED Medical Education: Prof. Karin Fijnvandraat, Professor of Paediatric Haematology at the University of Amsterdam in the Netherlands and Dr. Maria Elisa Mancuso, Senior Consultant in Haematology at IRCCS Humanitas Research Hospital in Milan, Italy, have an interesting discussion about prophylaxis in children with haemophilia. Along with five other members of the European Collaborative Haemophilia Network, Prof. Fijnvandraat and Dr. Mancuso recently published a white paper on prophylaxis in children in an evolving treatment landscape, in the journal Haemophilia.
In this podcast episode the two experts discuss when they start prophylaxis in young children, h...
2022-03-0328 min
COR2ED Medical EducationKey topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen...
2022-02-2813 min
COR2ED Medical EducationPARP inhibitors in prostate cancer: Management of adverse events and the importance of communication with patientsCOR2ED Medical Education: Dr Jason Alcorn, nurse consultant for Uro-Oncology & Andrology at the Mid Yorkshire Hospitals NHS Trust, United Kingdom and Dr Alicia Morgans, Genitourinary Medical Oncologist and Medical Director of the Survivorship Program at the Dana-Farber Cancer Institute in the United States, discuss 'PARP inhibitors in prostate cancer: Management of adverse events and the importance of communication with patients’ as part of the GU NURSES CONNECT podcast series covering ‘PARP inhibitors in prostate cancer’.
In this podcast, the experts discuss adverse events associated with PARP inhibitors and the management of them, in particular thrombocytopenia, gastrointestinal effect...
2022-02-1026 min
COR2ED Medical EducationInhibidores de PARP en cáncer de próstata: lo que las enfermeras necesitan saberCOR2ED Educación Médica: Pablo Peinado, coordinador de Enfermería de Investigación, y la Dra. Elena Castro, oncóloga médica, quienes trabajan en el Hospital Universitario Virgen de la Victoria de Málaga en España, discuten 'El potencial de los inhibidores de PARP en el cáncer de próstata: Lo que las enfermeras necesitan para saber'.
En este podcast, los expertos analizan los inhibidores de PARP (PARPi), cómo funcionan y los datos clave de los ensayos de registro de rucaparib y olaparib, TRITON2 y PROfound. También discuten cómo seleccionar P...
2022-02-0725 min
COR2ED Medical EducationPARP inhibitors in prostate cancer: What nurses need to know COR2ED Medical Education: Pablo Peinado, Research Nurse Coordinator, and Dr. Elena Castro, medical oncologist, who both work at Hospital Universitario Virgen de la Victoria in Malaga in Spain, discuss ‘The potential of PARP inhibitors in prostate cancer: What nurses need to know’.
In this podcast, the experts discuss PARP inhibitors (PARPi’s), how they work and key data from the registration trials for rucaparib and olaparib, TRITON2 and PROfound. They also discuss how to select PARPi’s for their prostate cancer patients and where they fit in the overall treatment sequence. Pablo provides some insight into communicat...
2022-02-0724 min
COR2ED Medical EducationGenetic testing and PARP inhibitors in prostate cancerCOR2ED Medical Education: Joanne Chien, Nurse Practitioner specialising in urologic cancers at Stanford Health Care in Palo Alto, California, and Dr Alexander Wyatt, Assistant Professor in genitourinary cancer genomics at the Vancouver Prostate Centre, Department of Urologic Sciences at the University of British Columbia, discuss ‘Genetic testing and PARP inhibitors in prostate cancer’ as part of the GU NURSES CONNECT podcast series covering ‘PARP inhibitors in prostate cancer’.
In this podcast, the experts discuss the gene alterations in prostate cancer and why we should consider genetic testing when thinking about treatment options such as PARP inhibitors (PARPi’s...
2022-01-2831 min
COR2ED Medical EducationThe role of VEGFR-TKIs in the treatment of advanced RCC alone or in combinationProf. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Prof. Georg Hutterer, a Urologist from the Medical University of Graz, Austria, discuss the role of VEGFR-TKIs in the treatment of advanced renal cell carcinoma (RCC) alone or in combination with immunotherapy.
In this podcast, by COR2ED Medical Education, the two experts discuss key trials (CHECKMATE 214, KEYNOTE 426, CHECKMATE 9ER and CLEAR) which have led to recent updates to the ESMO and EAU treatment guidelines for RCC. Combination treatment with either VEGFR targeted therapy plus a PD-1 or CTLA-4 inhibitor in the first-line...
2021-11-3020 min